Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Capital Expenditures (2016 - 2025)

Marimed (MRMD) has disclosed Capital Expenditures for 12 consecutive years, with $559000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 78.22% to $559000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 3.74% increase, with the full-year FY2024 number at $12.0 million, up 498.9% from a year prior.
  • Capital Expenditures was $559000.0 for Q3 2025 at Marimed, up from $309000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $12.1 million in Q4 2022 to a low of -$8.8 million in Q4 2023.
  • A 5-year average of $2.4 million and a median of $3.1 million in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 1579.83% in 2021, then plummeted 217.7% in 2022.
  • Marimed's Capital Expenditures stood at $3.2 million in 2021, then skyrocketed by 276.43% to $12.1 million in 2022, then plummeted by 172.4% to -$8.8 million in 2023, then surged by 112.04% to $1.1 million in 2024, then crashed by 47.16% to $559000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Capital Expenditures are $559000.0 (Q3 2025), $309000.0 (Q2 2025), and $266000.0 (Q1 2025).